Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BF-Lisinopril 20mg vs Zestril in Healthy Volunteers
NCT03599466Phase 1Unknown
- Sponsor
- Bright Future Pharmaceutical Laboratories Limited
- Start
- Oct 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of lisinopril in hypertension (HTN) (2 arms), sponsored by Bright Future Pharmaceutical Laboratories Limited. Primary endpoints: Peak plasma concentration of Lisinopril at 48 hours and Area under the plasma concentration versus time curve of Lisinopril at 48 hours. Status: unknown.
02
Drugs
lisinopril
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03599466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599466.